CAMP4 Therapeutics closes second tranche of private placement for $50.1 million
On August 3, 2026, CAMP4 Therapeutics completed the second closing of its private placement, selling common shares and pre-funded warrants for approximately $50.1 million in gross proceeds before placement agent fees and other expenses. The closing followed Australian clearance to start a Phase 1/2 trial of CMP-002 and a Price Threshold Waiver under the original agreement. The new shares and warrants add to the company's share count, and the company says the proceeds will support CMP-002 and its early-stage pipeline.
Key points
- Second closing on August 3, 2026 issued 10,756,498 shares at $1.53 and 21,925,368 pre-funded warrants at $1.5299 each.
- Gross proceeds of approximately $50.1 million, before placement agent fees and other expenses.
- Also sold 39,306 shares at $1.65 to certain management, directors and co-founders.
- Closing was triggered after July 2026 clearance for the CMP-002 Phase 1/2 trial in Australia; securities are unregistered and subject to a Registration Rights Agreement dated September 9, 2025.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.